

Special Issue

Circulating and Disseminated Tumor Cells – Novel Approaches and Future Outlook

Message from the Guest Editor

Despite major improvements in the diagnosis and treatment of solid tumors, many patients show a relapse in disease, often even years after first diagnosis, such as in breast cancer. In many cases, recurrence of the disease is explained by early micrometastatic spread of circulating tumor cells (CTCs) to blood and further dissemination into secondary organs such as the bone marrow (BM) to settle down there as disseminated tumor cells (DTCs). Although the clinical relevance for relapse and overall survival has been demonstrated in a variety of tumor entities based on the analysis of thousands of patients, the lack of therapeutic approaches to eliminate these cells constitutes a major obstacle to the successful treatment of the disease. Whereas multimarker detection methods are available for the characterization of CTCs, methods are lacking for DTCs because BM auto-fluorescence and endogenous immune cell properties as well as BM matrix components can generate false-positive staining. With the rapid technical progress in the detection of these cells, might help to evaluate patients for additional treatment options to eliminate minimal residual disease.

Guest Editor

Prof. Dr. Sabine Kasimir-Bauer

Department of Gynecology and Obstetrics, University Hospital Essen, 45147 Essen, Germany

Deadline for manuscript submissions

closed (31 January 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/97503

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)